This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.
All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy
by Zacks Equity Research
Oric Pharmaceuticals (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 105% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 131.3% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
by Zacks Equity Research
ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
by Zacks Equity Research
ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.
How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
by Zacks Equity Research
The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 39.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why
by Zacks Equity Research
Oric Pharmaceuticals, Inc. (ORIC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Oric Pharmaceuticals, Inc. (ORIC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Oric Pharmaceuticals, Inc. (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study
by Zacks Equity Research
ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.
AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition
by Zacks Equity Research
AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.
Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab
by Zacks Equity Research
Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.
Gilead's (GILD) Yescarta Gets EC Nod for New Cancer Indication
by Zacks Equity Research
The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma.
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce
by Zacks Equity Research
NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.
GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults
by Zacks Equity Research
GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.
Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.
BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance
by Zacks Equity Research
If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.
Acadia (ACAD) Thrives on Nuplazid, Overdependence a Concern
by Zacks Equity Research
Acadia's (ACAD) lead drug, Nuplazid, is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. Sole dependence on Nuplazid for growth remains an overhang.
Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion
by Zacks Equity Research
The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.
Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy
by Zacks Equity Research
Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.
Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why
by Zacks Equity Research
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.